Fig. 3: Neutralizing response against WT SARS-CoV-2 and VOC by prior SARS-CoV-2 infection status and type of COVID-19 vaccine.
a, Comparison of NAbT against WT SARS-CoV-2, Alpha, Beta and Delta in patients with previous infection before vaccination as compared to infection-naive patients after the second dose (n = 133 and 306 patients at baseline and FU3, respectively). Significance was tested by two-sided Wilcoxon–Mann–Whitney U-test; P < 0.05 was considered significant. b, Comparison of NAbT against WT SARS-CoV-2, Alpha, Beta and Delta in infection-naive patients (n = 318, 316, 253 and 307 patients at baseline, FU1, FU2 and FU3, respectively) versus patients previously infected with SARS-CoV-2 (n = 133, 163, 115 and 144 patients at baseline, FU1, FU2 and FU3). Comparison of NAbT against WT SARS-CoV-2, Alpha, Beta and Delta in infection-naive patients receiving AZ (n = 262, 246, 212 and 229 patients at baseline, FU1, FU2 and FU3, respectively) versus those receiving PZ (n = 56, 70, 41 and 77 patients at baseline, FU1, FU2 and FU3, respectively; one patient with unknown vaccine status was not included) (c) and in patients with previous SARS-CoV-2 infection receiving AZ (n = 99, 117, 92 and 91 patients at baseline, FU1, FU2 and FU3, respectively) versus those receiving PZ (n = 34, 46, 23 and 53 patients at baseline, FU1, FU2 and FU3, respectively) (d). The dotted line at <40 denotes the lower limit of detection; the dotted line at >2,560 denotes the upper limit of detection. Violin plots denote density of data points. The point range denotes the median and the 25th and 75th percentiles. Dots represent individual samples. Significance in b–d was tested by two-sided Wilcoxon–Mann–Whitney U-test; P < 0.05 was considered significant.
